TScan Therapeutics, Inc. (NASDAQ: TCRX) experienced a notable ascent of 10.46% on Tuesday, culminating in a closing value of $6.76. This surge in TScan’s stock value was precipitated by the disclosure of a significant corporate development.
TScan (TCRX) has officially communicated its intention to convene a virtual Key Opinion Leader (KOL) event scheduled for Monday, December 11, at 8:00 a.m. ET. During this event, TCRX will elucidate key insights derived from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the scripted remarks, the floor will be open for a dynamic question and answer session.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In addition to these corporate updates, TScan has welcomed Dr. Justin McCue as its Chief Technology Officer. Dr. McCue brings to TScan an extensive background, spanning more than two decades, in the realms of biologics and cell therapy manufacturing. His expertise encompasses process/analytical development, technical operations, clinical development, and the commercialization of T cell therapy products.
Previously associated with Avectas, a pioneering cell engineering technology company, Dr. McCue held the position of Chief Technology Officer, overseeing technology development and scientific strategy. His academic qualifications include a bachelor’s degree in chemical engineering from the University of California, Berkeley, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Furthermore, TScan has been honored as one of the Top Places to Work in Massachusetts as per the 16th annual employee-based survey project conducted by The Boston Globe. This prestigious recognition, featured online at Globe.com/TopPlaces and in the Globe Magazine on Sunday, December 3, 2023, underscores TScan’s commitment to being an exemplary workplace. The survey, gauging employee sentiments on various facets such as company direction, execution, connection, management, work, pay and benefits, and engagement, categorizes employers into size-specific groups.
Remarkably, TScan has clinched this accolade for the second consecutive year, underscoring its standing as a diligent, inclusive, and employee-centric organization. This achievement serves as a testament to the sustained excellence and dedication exhibited by the company.
